Research

Area 5

Hematological oncology

Team leader

Strategic objectives

The main strategic objectives of our team are clinical, applied and basic research in haematological oncology. The team is structured into three study groups of three major disease categories

Main lines of research

  1. Lymphoid neoplasms
    • Mechanisms of progression and study of the clinical significance of minimal residual disease.
    • Genomic profile of diffuse large cell lymphoma and its clinical significance (in collaboration with the National Cancer Institute (USA) and the Leukemia Lymphoma Molecular Profiling Project (LLMPP)).
    • New prognostic models in T cell lymphomas (in collaboration in international studies, particularly the International T-cell Lymphomas Project (University of Nebraska) and follicular lymphoma.
    • Mechanisms of progression of chronic lymphoid leukemia (CLL)
    • Influence of the cellular microenvironment in CLL.
    • Evaluation of cellular proliferation inCLL.
    • Project for theChronic Lymphocytic Leukemia (CLL) Genome, in collaboration with the Hematopathology Unit.
    • Phase I/II and III clinical trials in lymphomas and CLL.
  2. Multiple myeloma and other monoclonal gammopathies
    • Study of molecular cytogenics, gene-expression profile of cytokines related to angiogenesis and tumors microenvironment and analysis of genes differentially expressed in bone marrow and extramedullary plasmacytomas.
    • Evaluation of the immune reconstitution in patients in remission after autologous transplant or chemotherapy as compared with patients in partial response and monoclonal gammopathies of undetermined significance.
    • Impact of individual genetic variability on response to treatment in multiple myeloma through analysis of single nucleotide polymorphisms (SNPs).
    • Characterization of cardiac involvement in AL amyloidosis based on clinical presentation, cardiac biomarkers and imaging techniques, and influence of genetics in the predilection of light amyloidogenic chains for the heart and the severity of involvement.
    • Phase I, II and III clinical trials within the Spanish PETHEMA group or pharmaceutical companies.
  3. Myeloid neoplasms
    • Chronic myeloid leukemia (CML): Participation in the European Registry of CML
    • Philadelphia-negative myeloproliferative neoplasms: Mechanisms of thrombosis; relationship between mutational status and initial characteristics, progression and prognosis of myelofibrosis; participation in the European Registry of Myelofibrosis.
    • Acute myeloid leukemia (AML): Biological prognostic factors in AML of intermediate cytogenetic risk; Analysis of biological prognostic factors in AML; Analysis of expression of non-coding RNA (microRNA&long intergenic non-coding RNA) in AML; Design of treatment protocols for the Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias.
    • Myelodysplastic syndromes (MDS): Participation in the Spanish MDSRegistry; cytogenetic and molecular abnormalities and prognostic implications; study of microR-NA.
    • Phase I/II and III clinical trials with new drugs for CML, myelofibrosis, AML, ALL and MDS.

Research Group

Myeloma and other monoclonal gammapathies

Joan Bladé

(HCB)

Multiple Myeloma and systemic AL amyloidosis. Minimal residual disease and mechanisms of disease progression studies, extramedullary involvement in myeloma, cardiac involvement in Amyloidosis, and multicentric clinical trials with novel drugs.

Research Group

Myeloid neoplasms

Francisco Cervantes

(HCB)

Natural history and prognosis of chronic myeloid leukemia, myeloproliferative neoplasms, acute myeloid leukemia and myelodysplastic syndromes; prognostic importance of newer molecular markers in these diseases; clinical trials with new drugs.

Research Group

Lymphoid neoplasms

Armando López Guillermo

(HCB)

Lymphomas, chronic lymphocytic leukemia and the other lymphoproliferative disorders: Study of progression mechanisms of the disease, genome of CLL and lymphoma, minimum residual disease and biological prognostic models

50/50 Program

Mechanisms of progession in monoclonal gammopathies

Carlos Fernández de Larrea Rodríguez

(HCB-IDIBAPS)

Our group is focused on a comprehensive study on patients with multiple myeloma in complete remission, in order to investigate whether or not immune restoration is associated with the emergence of oligoclonal bands and to a continued response, and to search common features that these patients can share with those with long-lasting stable monoclonal gammopaties of undetermined significance (MGUS). For this purpose, a wide spectrum of biological studies in peripheral blood and bone marrow are performed in patients after transplantation or induction chemotherapy only, in comparison with patients with active myeloma.